Saturday 17 October 2026 Export LYEL’s income statement to Excel — free account

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

8.12 0.07 −0.85%

Follow LYEL

Alert me

Market cap: $200.7M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 2/9
Altman Z: −5.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
Piotroski F-Score Full definition →	+8 more TTM periods Free account	2	2	2	2
ROE Full definition →		(75.75%)	(86.98%)	(80.76%)	(93.28%)
ROA Full definition →		(63.41%)	(66.06%)	(63.15%)	(71.34%)
ROIC Full definition →		(2,256.68%)	(17,146.38%)	(815.53%)	(539.53%)
Return on Tangible Assets Full definition →		(97.78%)	(111.43%)	(93.66%)	(121.69%)
Average Days of Receivables Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →		(10.76)	(11.22)	(8.01)	(7.48)
Free Cash Flow Full definition →		(196.62)	(191.71)	(175.33)	(174.87)
Capital Expenditures Full definition →		(31.60)	(41.69)	(41.53)	(41.61)
Other line items
Cash ROIC Full definition →		(30.31%)	(38.70%)	(33.23%)	(39.93%)
Accounts Receivable Turnover Full definition →		0.00	0.00	0.00	0.00
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		378,400.00%	440,763.89%	489,780.65%	579,625.93%
Selling, General and Administrative Expense of Revenue Full definition →		119,612.20%	125,375.00%	131,109.68%	149,755.56%
Share Based Compensation of Revenue Full definition →		59,373.17%	116,191.67%	129,354.84%	146,770.37%
Operating CF/Net income Full definition →		0.51	0.55	0.54	0.54
Depreciation/Fixed assets Full definition →		0.20	0.19	0.19	0.19
Capex/Depreciation Full definition →		(4.33)	(6.34)	(6.58)	(7.25)
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(9.03)	(8.78)	(6.12)	(5.70)
Capex per Share Full definition →		(1.73)	(2.44)	(1.90)	(1.78)
Capex to Sales Full definition →		770.80	1,158.00	1,339.71	1,541.26

Show all line items

Columns are period end dates

Stockrow Weekly